Zobrazeno 1 - 10
of 92
pro vyhledávání: ''
Autor:
Bernhard Doleschal, Clemens Venhoda, Regina Prommer, Andreas L. Petzer, Holger Rumpold, Helwig Valentin Wundsam, Clemens A. Schmitt, Sigrid Metz-Gercek
Publikováno v:
Oncology. 98(10)
Background: Adenocarcinoma of the esophagogastric junction (AEG) is a rare but rising tumor entity in the Western world. Treatment is complex, as multimodality is key to optimal results. However, trials solely including AEG are rare, and the question
Publikováno v:
Oncology. 93:122-126
Objective: The aim of this study was to evaluate disease-specific survival and cost related to radioactive iodine therapy (RAI) utilization in patients with early-stage papillary thyroid carcinoma (PTC). Methods: This was a retrospective cohort study
Publikováno v:
Oncology. 92:190-196
Background: Although squamous cell anal carcinomas are relatively rare, their incidence has been increasing steadily. Because of the limited data, treatment of metastatic disease is a major therapeutic challenge. In this study, we report the safety a
Autor:
Kazuto Harada, Elena Elimova, Roopma Wadhwa, Brian D. Badgwell, Manoop S. Bhutani, Aurelio Matamoros, Jaffer A. Ajani, Nikolaos Charalampakis, Jeannelyn S. Estrella, Hironori Shiozaki, Bruce D. Minsky, Tara Sagebiel, Jane E. Rogers, Brian Weston, Jeffrey H. Lee, Prajnan Das, Mariela A. Blum, Graciela M. Nogueras González, Yusuke Shimodaira
Publikováno v:
Oncology. 90:239-247
Background: Patients with localized gastric adenocarcinoma (LGAC), who get pre-operative therapy, have heterogeneous/unpredictable outcomes. Predictive clinical variables/biomarkers are not established. Methods: We analyzed 107 LGAC patients who had
Autor:
Gaetano Facchini, Sabrina Chiara Cecere, Giampaolo De Palma, Carmela Pisano, Laura Arenare, Sandro Pignata, Stefano Greggi, Piera Gargiulo, Chiara Della Pepa, Rosa Tambaro, Marilena Di Napoli, Cono Scaffa, Sara Falivene
Publikováno v:
Oncology. 90:29-35
Objective: The aim of this study was to analyze the long-term toxicity and quality of life (QOL) in patients with locally advanced cervical cancer (LACC) treated with chemoradiation [chemotherapy/radiotherapy (CT/RT)] or neoadjuvant CT (NACT) followe
Autor:
Masanori Abe, Akiko Toshimori, Yoshifumi Suga, Nobuaki Azemoto, Tomoe Kawamura, Hiroka Yamago, Kojiro Michitaka, Masashi Hirooka, Tomonari Okudaira, Hideki Miyata, Hiromasa Nakahara, Tomoyuki Ninomiya, Yasunao Miyamoto, Hideki Kawasaki, Yoshihiro Ishimaru, Toshihiko Aibiki, Yoichi Hiasa, Atsushi Hiraoka, Bunzo Matsuura
Publikováno v:
Oncology. 89:167-174
Background/Aim: We examined tumor marker levels to assess in more detail transcatheter arterial chemoembolization (TACE)-refractory hepatocellular carcinoma (HCC). Materials and Methods: We enrolled patients treated from 2000 to 2011 for HCC beyond t
Autor:
Giorgia Perniola, Angela Musella, Laura Vertechy, Claudia Marchetti, Margherita Fischetti, Ilary Ruscito, Pierluigi Benedetti Panici, Innocenza Palaia, Violante Di Donato, Ludovico Muzii
Publikováno v:
Oncology. 89:103-110
Objective: To assess the efficacy and toxicity profile of dose-dense cisplatin-based neoadjuvant chemotherapy (NACT) followed by radical surgery in patients affected by locally advanced cervical cancer. Methods: Patients affected by carcinoma of the
Autor:
William J. Fulp, Richard D. Kim, William R. Dinwoodie, Amit Mahipal, Jennifer Byer, David Shibata
Publikováno v:
Oncology. 87:125-132
Background: The development of distant metastases of squamous cell carcinoma of the anal canal (SCCA) is rare but has a poor prognosis. A combination of carboplatin and paclitaxel is commonly used for treating squamous cell cancer in different organs
Publikováno v:
Oncology. 85:128-136
Background: Recent preclinical studies have shown that Forkhead box protein 3 (FOXP3) is an important tumor suppressor gene. The clinical and prognostic implication of FOXP3 expression in breast cancer cells still remains controversial. Methods: We e
Autor:
Jacques Medioni, Gero Kramer, Agnes Maj-Hes, Florian Scotté, Pierre Combe, Reza Elaidi, Stéphane Oudard, Yohan Gornadha, Manuela Schmidinger
Publikováno v:
Oncology. 85:8-13
Objective: To determine if mammalian target of rapamycin (mTOR) inhibitor (everolimus or temsirolimus) rechallenge in the third- or fourth-line setting after sequential use of a vascular endothelial growth factor receptor (VEGF)-targeted agent and an